MDT - Medtronic plc
| Previous close | 113.86 |
| Open | 113.59 |
| Bid | 112.67 x 1200 |
| Ask | 113.41 x 1100 |
| Day's range | 112.68 - 113.86 |
| 52-week range | 82.77 - 122.15 |
| Volume | 5,230,593 |
| Avg. volume | 4,399,077 |
| Market cap | 151.885B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 28.25 |
| EPS (TTM) | 4.01 |
| Earnings date | 20 May 2020 |
| Forward dividend & yield | 2.16 (1.90%) |
| Ex-dividend date | 25 Dec 2019 |
| 1y target est | 126.39 |
- Zacks
Stock Market News for Feb 19, 2020
Benchmarks ended mixed on Tuesday, as investors weighed the impact of the novel Coronavirus on global manufacturing supply chains and economy.
- Simply Wall St.
Does Medtronic plc's (NYSE:MDT) CEO Pay Matter?
In 2015 Omar Ishrak was appointed CEO of Medtronic plc (NYSE:MDT). This analysis aims first to contrast CEO...
- Zacks
Tandem Diabetes Hits New 52-Week High: What's Driving It?
Tandem Diabetes (TNDM) is optimistic about maintaining growth momentum on several recent developments.
- Zacks
Medtronic (MDT) Q3 Earnings Top Estimates, Revenues Miss
Medtronic (MDT) demonstrates better-than-expected Q3 performances at CER, backed by growth in all major business segments and geographies.
- Reuters
Medtronic misses revenue estimates, warns of coronavirus impact
Medtronic is the latest company to announce a potential impact to its financial results from the outbreak which has disrupted supply chains and delayed reopening of factories in China. Although its manufacturing operations in the country were up and running, Medtronic expects a negative impact from a slowdown in medical device procedures in the region. "Given the fluidity of this situation, the duration and magnitude of the impact are difficult to quantify at this time," Chief Executive Officer Omar Ishrak said on a conference call.
- Investing.com
Medtronic Stock Falls 3%
Investing.com - Medtronic (NYSE:MDT) Stock fell by 3.01% to trade at $113.77 by 09:40 (14:40 GMT) on Tuesday on the NYSE exchange.
- Investing.com
Medtronic Earnings Beat, Revenue Misses In Q3
Investing.com - Medtronic reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
- Zacks
Has Medtronic (MDT) Outpaced Other Medical Stocks This Year?
Is (MDT) Outperforming Other Medical Stocks This Year?
- Zacks
Medtronic Buys Digital Surgery, Boosts AI-Focus Surgical Care
Medtronic (MDT) to integrate Digital Surgery's business within its Surgical Robotics arm, in turn augmenting the company's position in the field of surgical AI.
- Zacks
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
- Zacks
Medtronic (MDT) Reports Next Week: Wall Street Expects Earnings Growth
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.
- Zacks
ZBH or MDT: Which Is the Better Value Stock Right Now?
ZBH vs. MDT: Which Stock Is the Better Value Option?
- Zacks
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
- Zacks
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know
Medtronic (MDT) closed at $119.99 in the latest trading session, marking a +1.7% move from the prior day.
- Zacks
Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark
Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.
- Zacks
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Medtronic (MDT) closed at $118.37, marking a -0.68% move from the previous day.
- Zacks
Medical Products' Earnings Due on Jan 29: ALGN, HOLX & More
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
- Zacks
New Alliances Aid Quest Diagnostics Despite Reimbursement Woes
Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.
- Simply Wall St.
If You Had Bought Medtronic (NYSE:MDT) Stock Five Years Ago, You Could Pocket A 64% Gain Today
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But in our...
- Zacks
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
Medtronic (MDT) closed the most recent trading day at $120.97, moving -0.1% from the previous trading session.
- Zacks
New Product Suite Boosts Intersect ENT Despite Cost Concerns
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
- Zacks
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block
Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
- Zacks
Zimmer Biomet Rides on Product Launches Despite Pricing Woes
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.
- Zacks
Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu
Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.
